{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:34:48Z","timestamp":1777563288815,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.jocn.2005.11.037","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T07:24:59Z","timestamp":1165994699000},"page":"153-157","source":"Crossref","is-referenced-by-count":9,"title":["Progressive ataxic gait disorder"],"prefix":"10.1016","volume":"14","author":[{"given":"Jayantha","family":"Rupasinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2005.11.037_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ana.410310307","article-title":"The spectrum of neurological disease in patients with systemic cancer","volume":"31","author":"Clouston","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2005.11.037_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0733-8619(18)30801-6","article-title":"The remote effects of cancer on the nervous system","volume":"7","author":"Dropcho","year":"1989","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jocn.2005.11.037_bib3","first-page":"97A","article-title":"Efficacy and safety of herceptin (humanized antiHER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer","volume":"17","author":"Cobleigh","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jocn.2005.11.037_bib4","first-page":"98A","article-title":"Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+\/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial","volume":"17","author":"Salmon","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jocn.2005.11.037_bib5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0733-8619(18)30257-3","article-title":"Paraneoplastic syndromes. Neurologic complications of systemic cancer","volume":"9","author":"Posner","year":"1991","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jocn.2005.11.037_bib6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1474-4422(02)00135-7","article-title":"Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, therapy","volume":"1","author":"Voltz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2005.11.037_bib7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0003-9993(00)90121-7","article-title":"Paraneoplastic cerebellar degeneration as the first evidence of cancer. A case report","volume":"81","author":"Liu","year":"2000","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jocn.2005.11.037_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1212\/WNL.55.5.713","article-title":"Long term clinical outcome of paraneoplastic cerebellar degeneration and anti Yo antibodies","volume":"55","author":"Rojas","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.11.037_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2000.18.3.632","article-title":"Over expression of HER 2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site","volume":"18","author":"Hainsworth","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2005.11.037_bib10","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/WNL.42.10.1931","article-title":"Paraneoplastic cerebellar degeneration. A clinical analysis of 55 anti-Yo antibody positive patients","volume":"42","author":"Peterson","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.11.037_bib11","unstructured":"Mehdi A, Ko DY. Paraneoplastic cerebellar degeneration. eMedicine Neurology Topic 299. Omaha, NE: eMedicine.com; updated March 21, 2006. Available at: http:\/\/www.emedicine.com\/neuro\/topic299.htm. Accessed June 2, 2006."},{"key":"10.1016\/j.jocn.2005.11.037_bib12","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2153::AID-CNCR16>3.0.CO;2-Y","article-title":"Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report","volume":"78","author":"David","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2005.11.037_bib13","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/1097-0142(19950401)75:7<1678::AID-CNCR2820750719>3.0.CO;2-2","article-title":"Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption","volume":"75","author":"Cher","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2005.11.037_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s004150050350","article-title":"Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders","volume":"246","author":"Blaes","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2005.11.037_bib15","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/archneur.1995.00540320098016","article-title":"Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration","volume":"52","author":"Stark","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2005.11.037_bib16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/WNL.42.3.536","article-title":"Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies","volume":"42","author":"Graus","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2005.11.037_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1750-3639.1999.tb00226.x","article-title":"Paraneoplastic neurological syndromes: pathogenensis and physiopathology","volume":"9","author":"Dalmau","year":"1999","journal-title":"Brain Pathol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586806003560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586806003560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T18:05:49Z","timestamp":1555956349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586806003560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0967586806003560"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2005.11.037","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}